Kiora rises on nod to start mid-stage study of eye drug

Kiora Pharmaceuticals

07/02/2023 12:41

** Shares of drug developer Kiora Pharmaceuticals Inc
 KPRX.O  rise ~54% premarket to $5.05, among top pct gainers
across U.S. exchanges
    ** Receives approval to start mid-stage study of its drug
KIO-101 for the treatment of the eye conditions related to
rheumatoid arthritis and other autoimmune diseases
    ** Study expected to begin enrolling patients in Australia
in the first half of 2023 and will assess safety and efficacy of
the eye drops in about 120 patients
    ** Stock lost ~94% last year
 (Reporting by Sriparna Roy)
 ((Sriparna.Roy@thomsonreuters.com;))